Utility of the 21-Gene Recurrence Score in Node-Positive Breast Cancer
Cancer Network,
Introduction Insights from gene expression profiling have vastly expanded our understanding of distinct molecular subtypes of…
Introduction Insights from gene expression profiling have vastly expanded our understanding of distinct molecular subtypes of…
Should chemotherapy be standard treatment for all patients with early-stage breast cancer with positive lymph nodes? When…
Additional large population-based study indicates not all young women under 40 years with node negative breast cancer have…
SOURCE Genomic Health, Inc. New SEER Registry Analysis Indicates Many Young Women Under 40 Years with Node-negative Breast…
Information contained on this page is provided by an independent third-party content provider.
SOURCE Genomic Health, Inc. New SEER Registry Analysis Indicates Many Young Women Under 40 Years with Node-negative Breast…
SOURCE Genomic Health, Inc. New SEER Registry Analysis Indicates Many Young Women Under 40 Years with Node-negative Breast…
SOURCE Genomic Health, Inc. New SEER Registry Analysis Indicates Many Young Women Under 40 Years with Node-negative Breast…
SOURCE Genomic Health, Inc. New SEER Registry Analysis Indicates Many Young Women Under 40 Years with Node-negative Breast…
SOURCE Genomic Health, Inc. New SEER Registry Analysis Indicates Many Young Women Under 40 Years with Node-negative Breast…
SOURCE Genomic Health, Inc. New SEER Registry Analysis Indicates Many Young Women Under 40 Years with Node-negative Breast…
SOURCE Genomic Health, Inc. New SEER Registry Analysis Indicates Many Young Women Under 40 Years with Node-negative Breast…
SOURCE Genomic Health, Inc. New SEER Registry Analysis Indicates Many Young Women Under 40 Years with Node-negative Breast…
SOURCE Genomic Health, Inc. New SEER Registry Analysis Indicates Many Young Women Under 40 Years with Node-negative Breast…
SOURCE Genomic Health, Inc. New SEER Registry Analysis Indicates Many Young Women Under 40 Years with Node-negative Breast…
SOURCE Genomic Health, Inc. New SEER Registry Analysis Indicates Many Young Women Under 40 Years with Node-negative Breast…
SOURCE Genomic Health, Inc. New SEER Registry Analysis Indicates Many Young Women Under 40 Years with Node-negative Breast…
Information contained on this page is provided by an independent third-party content provider.
SOURCE Genomic Health, Inc. New SEER Registry Analysis Indicates Many Young Women Under 40 Years with Node-negative Breast…
SOURCE Genomic Health, Inc. New SEER Registry Analysis Indicates Many Young Women Under 40 Years with Node-negative Breast…
SOURCE Genomic Health, Inc. New SEER Registry Analysis Indicates Many Young Women Under 40 Years with Node-negative Breast…
SOURCE Genomic Health, Inc. New SEER Registry Analysis Indicates Many Young Women Under 40 Years with Node-negative Breast…
SOURCE Genomic Health, Inc. New SEER Registry Analysis Indicates Many Young Women Under 40 Years with Node-negative Breast…
SOURCE Genomic Health, Inc. New SEER Registry Analysis Indicates Many Young Women Under 40 Years with Node-negative Breast…
SOURCE Genomic Health, Inc. New SEER Registry Analysis Indicates Many Young Women Under 40 Years with Node-negative Breast…
SOURCE Genomic Health, Inc. New SEER Registry Analysis Indicates Many Young Women Under 40 Years with Node-negative Breast…
SOURCE Genomic Health, Inc. New SEER Registry Analysis Indicates Many Young Women Under 40 Years with Node-negative Breast…
SOURCE Genomic Health, Inc. New SEER Registry Analysis Indicates Many Young Women Under 40 Years with Node-negative Breast…
SOURCE Genomic Health, Inc. New SEER Registry Analysis Indicates Many Young Women Under 40 Years with Node-negative Breast…
SOURCE Genomic Health, Inc. New SEER Registry Analysis Indicates Many Young Women Under 40 Years with Node-negative Breast…
SOURCE Genomic Health, Inc. New SEER Registry Analysis Indicates Many Young Women Under 40 Years with Node-negative Breast…
SOURCE Genomic Health, Inc. New SEER Registry Analysis Indicates Many Young Women Under 40 Years with Node-negative Breast…
SOURCE Genomic Health, Inc. New SEER Registry Analysis Indicates Many Young Women Under 40 Years with Node-negative Breast…
SOURCE Genomic Health, Inc. New SEER Registry Analysis Indicates Many Young Women Under 40 Years with Node-negative Breast…
SOURCE Genomic Health, Inc. New SEER Registry Analysis Indicates Many Young Women Under 40 Years with Node-negative Breast…
SOURCE Genomic Health, Inc. New SEER Registry Analysis Indicates Many Young Women Under 40 Years with Node-negative Breast…
SOURCE Genomic Health, Inc. New SEER Registry Analysis Indicates Many Young Women Under 40 Years with Node-negative Breast…
SOURCE Genomic Health, Inc. New SEER Registry Analysis Indicates Many Young Women Under 40 Years with Node-negative Breast…
SOURCE Genomic Health, Inc. New SEER Registry Analysis Indicates Many Young Women Under 40 Years with Node-negative Breast…
SOURCE Genomic Health, Inc. New SEER Registry Analysis Indicates Many Young Women Under 40 Years with Node-negative Breast…
SOURCE Genomic Health, Inc. New SEER Registry Analysis Indicates Many Young Women Under 40 Years with Node-negative Breast…
SOURCE Genomic Health, Inc. New SEER Registry Analysis Indicates Many Young Women Under 40 Years with Node-negative Breast…
SOURCE Genomic Health, Inc. New SEER Registry Analysis Indicates Many Young Women Under 40 Years with Node-negative Breast…
SOURCE Genomic Health, Inc. New SEER Registry Analysis Indicates Many Young Women Under 40 Years with Node-negative Breast…
SOURCE Genomic Health, Inc. New SEER Registry Analysis Indicates Many Young Women Under 40 Years with Node-negative Breast…
SOURCE Genomic Health, Inc. New SEER Registry Analysis Indicates Many Young Women Under 40 Years with Node-negative Breast…
SOURCE Genomic Health, Inc. New SEER Registry Analysis Indicates Many Young Women Under 40 Years with Node-negative Breast…
REDWOOD CITY, Calif., Sept. 11, 2017 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced the presentation of…
PR Newswire REDWOOD CITY, Calif., Sept. 11, 2017 REDWOOD CITY, Calif., Sept. 11, 2017 /PRNewswire/ -- Genomic Health, Inc.
New SEER Registry Analysis Indicates Many Young Women Under 40 Years with Node-negative Breast Cancer Do Not Have Aggressive…
REDWOOD CITY, Calif., Sept. 11, 2017 /PRNewswire/ --. (Nasdaq: ) today announced the presentation of new data that provide…
REDWOOD CITY, Calif. Results from a first-of-its-kind analysis including over 6,000 patients younger than age 40 from the…
New SEER Registry Analysis Indicates Many Young Women Under 40 Years with Node-negative Breast Cancer Do Not Have Aggressive…
REDWOOD CITY, Calif., Sept. 11, 2017 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced the presentation of…
Additional large population-based study indicates not all young women under 40 years with node negative breast cancer have…
REDWOOD CITY, Calif., Sept. 11, 2017 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced the presentation of…
REDWOOD CITY, Calif., Aug. 1, 2017 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today reported financial results and…
SOURCE Genomic Health, Inc. Delivered 9 Percent Increase in Test Volume; 4 Percent Increase in Revenue Continued to Generate…
SOURCE Genomic Health, Inc. Delivered 9 Percent Increase in Test Volume; 4 Percent Increase in Revenue Continued to Generate…
SOURCE Genomic Health, Inc. Delivered 9 Percent Increase in Test Volume; 4 Percent Increase in Revenue Continued to Generate…
SOURCE Genomic Health, Inc. Delivered 9 Percent Increase in Test Volume; 4 Percent Increase in Revenue Continued to Generate…
SOURCE Genomic Health, Inc. Delivered 9 Percent Increase in Test Volume; 4 Percent Increase in Revenue Continued to Generate…
Information contained on this page is provided by an independent third-party content provider.
SOURCE Genomic Health, Inc. Delivered 9 Percent Increase in Test Volume; 4 Percent Increase in Revenue Continued to Generate…
SOURCE Genomic Health, Inc. Delivered 9 Percent Increase in Test Volume; 4 Percent Increase in Revenue Continued to Generate…
SOURCE Genomic Health, Inc. Delivered 9 Percent Increase in Test Volume; 4 Percent Increase in Revenue Continued to Generate…
SOURCE Genomic Health, Inc. Delivered 9 Percent Increase in Test Volume; 4 Percent Increase in Revenue Continued to Generate…
SOURCE Genomic Health, Inc. Delivered 9 Percent Increase in Test Volume; 4 Percent Increase in Revenue Continued to Generate…
SOURCE Genomic Health, Inc. Delivered 9 Percent Increase in Test Volume; 4 Percent Increase in Revenue Continued to Generate…
SOURCE Genomic Health, Inc. Delivered 9 Percent Increase in Test Volume; 4 Percent Increase in Revenue Continued to Generate…
SOURCE Genomic Health, Inc. Delivered 9 Percent Increase in Test Volume; 4 Percent Increase in Revenue Continued to Generate…
Information contained on this page is provided by an independent third-party content provider.
SOURCE Genomic Health, Inc. Delivered 9 Percent Increase in Test Volume; 4 Percent Increase in Revenue Continued to Generate…
SOURCE Genomic Health, Inc. Delivered 9 Percent Increase in Test Volume; 4 Percent Increase in Revenue Continued to Generate…
SOURCE Genomic Health, Inc. Delivered 9 Percent Increase in Test Volume; 4 Percent Increase in Revenue Continued to Generate…
SOURCE Genomic Health, Inc. Delivered 9 Percent Increase in Test Volume; 4 Percent Increase in Revenue Continued to Generate…
SOURCE Genomic Health, Inc. Delivered 9 Percent Increase in Test Volume; 4 Percent Increase in Revenue Continued to Generate…
SOURCE Genomic Health, Inc. Delivered 9 Percent Increase in Test Volume; 4 Percent Increase in Revenue Continued to Generate…
SOURCE Genomic Health, Inc. Delivered 9 Percent Increase in Test Volume; 4 Percent Increase in Revenue Continued to Generate…
SOURCE Genomic Health, Inc. Delivered 9 Percent Increase in Test Volume; 4 Percent Increase in Revenue Continued to Generate…
SOURCE Genomic Health, Inc. Delivered 9 Percent Increase in Test Volume; 4 Percent Increase in Revenue Continued to Generate…
SOURCE Genomic Health, Inc. Delivered 9 Percent Increase in Test Volume; 4 Percent Increase in Revenue Continued to Generate…
SOURCE Genomic Health, Inc. Delivered 9 Percent Increase in Test Volume; 4 Percent Increase in Revenue Continued to Generate…
SOURCE Genomic Health, Inc. Delivered 9 Percent Increase in Test Volume; 4 Percent Increase in Revenue Continued to Generate…
SOURCE Genomic Health, Inc. Delivered 9 Percent Increase in Test Volume; 4 Percent Increase in Revenue Continued to Generate…
SOURCE Genomic Health, Inc. Delivered 9 Percent Increase in Test Volume; 4 Percent Increase in Revenue Continued to Generate…
SOURCE Genomic Health, Inc. Delivered 9 Percent Increase in Test Volume; 4 Percent Increase in Revenue Continued to Generate…
SOURCE Genomic Health, Inc. Delivered 9 Percent Increase in Test Volume; 4 Percent Increase in Revenue Continued to Generate…
SOURCE Genomic Health, Inc. Delivered 9 Percent Increase in Test Volume; 4 Percent Increase in Revenue Continued to Generate…
SOURCE Genomic Health, Inc. Delivered 9 Percent Increase in Test Volume; 4 Percent Increase in Revenue Continued to Generate…
SOURCE Genomic Health, Inc. Delivered 9 Percent Increase in Test Volume; 4 Percent Increase in Revenue Continued to Generate…
SOURCE Genomic Health, Inc. Delivered 9 Percent Increase in Test Volume; 4 Percent Increase in Revenue Continued to Generate…
SOURCE Genomic Health, Inc. Delivered 9 Percent Increase in Test Volume; 4 Percent Increase in Revenue Continued to Generate…
SOURCE Genomic Health, Inc. Delivered 9 Percent Increase in Test Volume; 4 Percent Increase in Revenue Continued to Generate…
SOURCE Genomic Health, Inc. Delivered 9 Percent Increase in Test Volume; 4 Percent Increase in Revenue Continued to Generate…
SOURCE Genomic Health, Inc. Delivered 9 Percent Increase in Test Volume; 4 Percent Increase in Revenue Continued to Generate…
SOURCE Genomic Health, Inc. Delivered 9 Percent Increase in Test Volume; 4 Percent Increase in Revenue Continued to Generate…
SOURCE Genomic Health, Inc. Delivered 9 Percent Increase in Test Volume; 4 Percent Increase in Revenue Continued to Generate…
SOURCE Genomic Health, Inc. Delivered 9 Percent Increase in Test Volume; 4 Percent Increase in Revenue Continued to Generate…
SOURCE Genomic Health, Inc. Delivered 9 Percent Increase in Test Volume; 4 Percent Increase in Revenue Continued to Generate…